Key facts
- This page summarizes Alison Bauerlein's Form 4 filing for Sight Sciences, Inc. (SGHT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 16 Feb 2024, 21:36.
Alison Bauerlein - 14 Feb 2024 Form 4 Insider Report for Sight Sciences, Inc. (SGHT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SGHT
- Reported as of
- 14 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Feb 2024, 21:36:23 UTC
- Prior SEC filing
- 11 May 2023
- Next SEC filing
- 04 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeremy Hayden, Attorney-in-Fact for Alison Bauerlein
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alison Bauerlein filed Form 4 for Sight Sciences, Inc. (SGHT) on 16 Feb 2024.
Change
- Previous filing in this sequence was filed on 11 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGHT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- -315,421
- Change %
- -42%
- Price
- $0.000000
- Shares after
- 436,371
- Date
- 14 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2024 and continuing through December 31, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $1,350,000 divided by the closing price of the Common Stock on the grant date, which was February 14, 2024. The RSUs have no expiration date.
Footnote F2
Includes 17,950 shares of Common Stock issuable upon the Reporting Person's exercise of options that shall vest within 60 days of the date hereof subject to the Reporting Person's continued service to the Issuer through such vesting date.